| niacin extended-release formulation / Generic mfg. |
NCT00590629: Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women |
|
|
| Completed | 4 | 43 | US | Niaspan | Cedars-Sinai Medical Center, General Clinical Research Center (GCRC), Kos Pharmaceuticals | Coronary Artery Disease | 11/05 | 11/05 | | |
NCT00298909: Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL) |
|
|
| Completed | 4 | 48 | Europe | physical exercise, niaspan (extended-release niacin), niacin, control | University of Leipzig | Coronary Disease, Hypolipoproteinemia | 06/09 | 06/09 | | |
HALTS, NCT00397657: Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis |
|
|
| Terminated | 4 | 400 | US | extended release niacin, ezetimibe | Walter Reed Army Medical Center, Abbott | Atherosclerosis | 08/09 | 10/09 | | |
|
NCT01052311: The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients |
|
|
| Terminated | 4 | 8 | RoW | Tredaptive (1 g extended release niacin+ 20 mg laropiprant), Active treatment, Placebo, Tredaptive, Tedaptive | Sheba Medical Center | Coronary Artery Disease, Dyslipidemia | 01/13 | 01/13 | | |
NCT01308203: Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease |
|
|
| Terminated | 4 | 32 | RoW | Extended release niacin/laropiprant, placebo | Daniel A. Siniawski, Merck Sharp & Dohme LLC | Coronary Artery Disease, Dyslipidemias | 01/13 | 01/13 | | |
